Tc 99m glucarate

Drug Profile

Tc 99m glucarate

Alternative Names: AMISCAN; Tc-99m-glucarate; Technetium glucarate; Technetium Tc 99m glucarate

Latest Information Update: 03 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Targeting Technologies
  • Developer DRAXIS Specialty Pharmaceuticals; Molecular Targeting Technologies
  • Class Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Sugar acids; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute coronary syndromes

Most Recent Events

  • 03 Aug 2015 No recent reports on development identified - Phase-II for Acute coronary syndromes (Diagnosis) in USA and Canada (IV)
  • 05 Jan 2005 DRAXIS Pharma has merged with DRAXIMAGE to form DRAXIS Specialty Pharmaceuticals
  • 25 Jul 2003 DRAXIMAGE and Bristol-Myers Squibb Imaging have extended and expanded their existing agreement in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top